In addition, our data also showed that CNG of EGFR, HER3 and HER4 significantly shortened median survival times of the patients with early-stage tumors, but had very little effect on the survival of the patients with late-stage tumors, further supporting that these abnormalities may be early genetic events in glioma tumorigenesis. This evidence concerns the gene EGFR and glioma.